BioNTech to license bispecific antibody to Bristol in up to $11.1B deal

Bristol Myers Squibb (NYSE:BMY) is paying up to $11.1B in a licensing agreement to help develop BioNTech’s (NASDAQ:BNTX) immunotherapy bispecific antibody BNT327 for solid tumors.

The candidate, which targets PD-L1 and VEGF-A, is in several ongoing trials, including one in phase 3 as